Register to chat with like-minded investors on our interactive forums.

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next >>

Date	Time	Source	Headline	Symbol	Company
06/09/2023	3:00AM	PR Newswire (US)	AbbVie's VENCLYXTO®/VENCLEXTA® (venetoclax) Continues to Show Sustained Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) Patients	NYSE:ABBV	AbbVie Inc
06/07/2023	7:01AM	PR Newswire (Canada)	AbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program	NYSE:ABBV	AbbVie Inc
06/07/2023	7:01AM	PR Newswire (Canada)	AbbVie annonce le remboursement de VRAYLAR® (cariprazine) pour le traitement de la schizophrénie en vertu du Programme des services de santé non assurés (SSNA)	NYSE:ABBV	AbbVie Inc
06/06/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference	NYSE:ABBV	AbbVie Inc
06/01/2023	2:59AM	Dow Jones News	AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program	NYSE:ABBV	AbbVie Inc
05/31/2023	2:30AM	PR Newswire (US)	Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus	NYSE:ABBV	AbbVie Inc
05/25/2023	8:45AM	PR Newswire (US)	New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease	NYSE:ABBV	AbbVie Inc
05/24/2023	9:00AM	PR Newswire (US)	AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress	NYSE:ABBV	AbbVie Inc
05/19/2023	12:34PM	PR Newswire (US)	EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	NYSE:ABBV	AbbVie Inc
05/18/2023	1:55PM	Dow Jones News	AbbVie Gets FDA Expanded Nod for Rinvoq in Crohn's Disease	NYSE:ABBV	AbbVie Inc
05/18/2023	12:25PM	PR Newswire (US)	U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults	NYSE:ABBV	AbbVie Inc
05/15/2023	8:45AM	PR Newswire (US)	SKINVIVE™ by JUVÉDERM® Receives U.S. FDA Approval	NYSE:ABBV	AbbVie Inc
05/12/2023	5:00PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
05/10/2023	5:11PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
05/09/2023	5:06PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
05/09/2023	5:05PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
05/09/2023	5:04PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
05/09/2023	5:04PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
05/09/2023	5:02PM	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NYSE:ABBV	AbbVie Inc
05/09/2023	7:01AM	PR Newswire (Canada)	Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)	NYSE:ABBV	AbbVie Inc
05/09/2023	7:01AM	PR Newswire (Canada)	AbbVie reçoit l'approbation de Santé Canada pour l'emploi de RINVOQ® (upadacitinib) dans le traitement des adultes atteints de spondylarthrite axiale non radiographique évolutive	NYSE:ABBV	AbbVie Inc
05/06/2023	7:30AM	PR Newswire (US)	AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®	NYSE:ABBV	AbbVie Inc
05/05/2023	12:59PM	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:ABBV	AbbVie Inc
05/04/2023	8:09AM	Edgar (US Regulatory)	Notice of Exempt Solicitation. Definitive Material. (px14a6g)	NYSE:ABBV	AbbVie Inc
05/02/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the Bank of America Securities Healthcare Conference	NYSE:ABBV	AbbVie Inc
04/27/2023	5:01PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
04/27/2023	10:46AM	Dow Jones News	AbbVie Down Nearly 7%, on Track for Largest Percent Decrease Since September 2021 -- Data Talk	NYSE:ABBV	AbbVie Inc
04/27/2023	7:37AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
04/27/2023	7:32AM	PR Newswire (US)	AbbVie Reports First-Quarter 2023 Financial Results	NYSE:ABBV	AbbVie Inc
04/25/2023	4:17PM	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next >>

FBEC Worldwide (CE)

Clean Vision (QB)

Enzolytics (PK)

Ronn Motor (PK)

Elite Pharmaceuticals (QB)

ERHC Energy (CE)

Valiant Eagle (PK)

Voip Pal Com (QB)

Ubiquitech Software (PK)

Digital Brand Media and ... (PK)

Fannie Mae (QB)

Delayed Upgrade Clock